CN109276637B - 韭菜子提取物及其制备方法和在制备保肝护肝药物方面的应用 - Google Patents
韭菜子提取物及其制备方法和在制备保肝护肝药物方面的应用 Download PDFInfo
- Publication number
- CN109276637B CN109276637B CN201811353323.3A CN201811353323A CN109276637B CN 109276637 B CN109276637 B CN 109276637B CN 201811353323 A CN201811353323 A CN 201811353323A CN 109276637 B CN109276637 B CN 109276637B
- Authority
- CN
- China
- Prior art keywords
- allii tuberosi
- semen allii
- extract
- liver
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 65
- 210000000582 semen Anatomy 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000000605 extraction Methods 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 206010067125 Liver injury Diseases 0.000 claims abstract description 20
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 17
- 210000005228 liver tissue Anatomy 0.000 claims abstract description 16
- 238000010828 elution Methods 0.000 claims abstract description 11
- 230000002708 enhancing effect Effects 0.000 claims abstract description 9
- 239000011347 resin Substances 0.000 claims abstract description 8
- 229920005989 resin Polymers 0.000 claims abstract description 8
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 7
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- 238000001179 sorption measurement Methods 0.000 claims abstract description 3
- 239000003463 adsorbent Substances 0.000 claims description 5
- 230000003064 anti-oxidating effect Effects 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 19
- 230000004224 protection Effects 0.000 abstract description 8
- 238000005406 washing Methods 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 208000037816 tissue injury Diseases 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 229910052799 carbon Inorganic materials 0.000 description 16
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 244000003377 Allium tuberosum Species 0.000 description 12
- 235000005338 Allium tuberosum Nutrition 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 240000006108 Allium ampeloprasum Species 0.000 description 10
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 10
- 239000008103 glucose Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 8
- 229930002600 steroidal saponin Natural products 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- PTMUTMGEBGQTEJ-UHFFFAOYSA-N tuberoside d Chemical compound O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CCC4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O PTMUTMGEBGQTEJ-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- -1 oxygen free radical Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 150000005856 steroid saponins Chemical class 0.000 description 4
- WROHFEWGWYQNPP-LRVYEFJLSA-N trigoneoside Xa Natural products O(C[C@H](CC[C@]1(O)[C@@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@@H](O)[C@@H](CO)O6)[C@H](O)C5)CC4)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 WROHFEWGWYQNPP-LRVYEFJLSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- OHZYISZWOVEBCJ-ATLCLBDSSA-N Tuberoside Chemical compound O([C@@H]1C[C@]2(O)[C@H](O)C=C3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OHZYISZWOVEBCJ-ATLCLBDSSA-N 0.000 description 3
- 231100000439 acute liver injury Toxicity 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000013245 carbon tetrachloride model Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- OHZYISZWOVEBCJ-UHFFFAOYSA-N tuberoside Natural products C1CC2(C)C3CCC4(C)C(C(C)C=CC(C)C(C)C)CCC4C3=CC(O)C2(O)CC1OC1OC(CO)C(O)C(O)C1O OHZYISZWOVEBCJ-UHFFFAOYSA-N 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- GHSUIFMSMQVPPS-UHFFFAOYSA-N 26-O-D-Glucopyranosyl-(25R)-322•,26-trihydroxyl-5furostane 3-O-chacotrioside Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5)C)(O)OC1CC2C3CCC4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O GHSUIFMSMQVPPS-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000989913 Gunnera petaloidea Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- SGRRIJHJAPNORJ-UHFFFAOYSA-N neoprotodioscin Natural products CC(CCC1(O)OC2CC3C4CCC5CC(CCC5(C)C4CCC3(C)C2C1C)OC6OC(CO)C(O)(OC7OC(C)C(O)C(O)C7O)C(O)C6OC8OC(C)C(O)C(O)C8O)COC9OC(CO)C(O)C(O)C9O SGRRIJHJAPNORJ-UHFFFAOYSA-N 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- INLFWQCRAJUDCR-LYLBMTSKSA-N spirostane group Chemical class [C@@H]12C[C@@H]3O[C@]4(CC[C@@H](C)CO4)[C@@H](C)[C@@H]3[C@@]1(C)CC[C@H]1[C@H]2CCC2CCCC[C@]12C INLFWQCRAJUDCR-LYLBMTSKSA-N 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000234282 Allium Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GMBQZIIUCVWOCD-UQHLGXRBSA-N Isosarsasapogenin Natural products O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 244000014047 Polianthes tuberosa Species 0.000 description 1
- 235000016067 Polianthes tuberosa Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- WROHFEWGWYQNPP-UCDNYNMGSA-N Trigoneoside Xb Chemical compound CC(CCC1(O)OC2CC3C4CCC5CC(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O[C@@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O)C(O)CC5(C)C4CCC3(C)C2C1C)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WROHFEWGWYQNPP-UCDNYNMGSA-N 0.000 description 1
- WROHFEWGWYQNPP-TWTXRAJDSA-N Trigoneoside Xb Natural products O(C[C@@H](CC[C@]1(O)[C@@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@@H](O)[C@@H](CO)O6)[C@H](O)C5)CC4)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 WROHFEWGWYQNPP-TWTXRAJDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000020931 dietary conditions Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229930190154 trigonoside Natural products 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种韭菜子提取物的制备方法,其将粉碎后的韭菜子、炒韭菜子或盐炙韭菜子用20-50%乙醇进行闪式提取,提取液浓缩后分散在水中,然后用二氯甲烷进行萃取,萃取所得水层经大孔吸附树脂吸附后用水冲洗,最后用30-60%乙醇进行梯度洗脱,合并梯度洗脱所得的洗脱液,经浓缩、干燥即得。经实验研究发现:韭菜子提取物可以拮抗四氯化碳引起的小鼠肝组织损伤,且具有一定的保护作用,以及具有加强肝损伤小鼠机体的抗氧化功能,保护肝组织免受自由基进一步伤害的作用和功效。
Description
技术领域
本发明属于植物提取技术领域,具体涉及一种韭菜子提取物、制备方法及其在制备保护肝损伤食品、保健品以及药物中的新应用。
背景技术
肝脏是人体的重要器官,它是物质合成与代谢、能量产生和转换的重要枢纽。肝脏暴露于有害条件下如药物、化学试剂、辐射等均可引起急性肝损伤,长期作用可导致不可修复的损伤,并发生代偿性修复,即形成肝纤维化,进一步可发展成肝硬化或肝癌。由于山区和乡镇的卫生、饮食条件较差,所以山区和乡镇人口肝病发病率最高。中药应用于肝脏疾病的预防和治疗已有数千年的历史,其具有提高免疫力,调节肝脏功能,改善肝脏血液循环,有效修复肝脏等功效。中药有效成分可以通过抗氧自由基损伤、减少炎症和凋亡相关介质的产生、改善肝功能、改善微循环、调节免疫功能等途径达到保护肝细胞治疗肝损伤的作用。但是,目前市场上保肝药较贵,对于山区和乡镇的消费者来说负担较重。因此,开发有效预防、治疗和价位低廉的保肝功能性食品、保健品或药物具有重要意义。
韭菜子(Semen Allii Tuberose)是百合科葱属多年生植物韭菜(Alliium tuberosum Rottl. Ex Spreng.)的干燥成熟种子,为药食同源的中药,具有益肾、健脾提神、行气理血、润肠通便、壮阳固精等功效,用于肾亏虚,腰膝酸痛,阳痿遗精等,收载于《中国药典》第一部。研究表明韭菜子化学成分主要有甾体皂苷类、生物碱类、硫化物、黄酮类等化合物。现代药理研究证明韭菜子具有温肾壮阳、加强免疫、抗氧化、抗衰老、抑菌等作用。韭菜子为韭菜生产的附属产品,近年市场保健品行业对韭菜子需求快速增长,韭菜种植面积变得更为广泛、货源充足,使价格一直保持在平稳、合理阶段。对于开发高效、低价的保肝药,解决“看病难,看病贵”具有重要意义。目前,并未有韭菜子在保肝护肝方面应用的文献相关报道。
发明内容
本发明目的在于克服现有技术缺陷,提供一种价格低廉、制备简单的韭菜子提取物。
本发明还提供了上述韭菜子提取物的制备方法及其在制备保护肝损伤食品、保健品以及药物中的新应用。
为实现上述目的,本发明采用如下技术方案:
一种韭菜子提取物的制备方法,将粉碎后的韭菜子、炒韭菜子或盐炙韭菜子用20-50%乙醇进行闪式提取,提取液浓缩后分散在水中,然后用二氯甲烷进行萃取,萃取所得水层部位经大孔吸附树脂吸附后用水冲洗,最后用30-60%乙醇进行梯度洗脱,合并梯度洗脱所得的洗脱液,经浓缩、干燥即得到韭菜子总甾体皂苷。
上述韭菜子提取物的制备方法,具体的,闪式提取可以进行2-3次,闪式提取时每1 g 韭菜子、炒韭菜子或盐炙韭菜子以添加8-15mL的20-50%乙醇为宜。
具体的,上述韭菜子提取物的制备方法中,每次闪式提取的时间为3-10min。
具体的,上述韭菜子提取物的制备方法中,二氯甲烷萃取次数为2-3次。
具体的,上述韭菜子提取物的制备方法中,所述大孔吸附树脂的型号为HPD100,HPD600,HPD400,D101,AB-8,ADS-17或DM130等。
本发明提供了采用上述方法制备得到的韭菜子提取物,其中总甾体皂苷类化合物含量>80%。经检测发现:制备所得韭菜子提取物中主要包括五种甾体皂苷类化合物,总含量>50%,分别是:
化合物1:26-O-β-D-吡喃葡萄糖基-25(R)-5α-呋甾烷-3β, 22α, 26-三羟基-3-O-[α-L-吡喃鼠李糖基-(1→2)-O-α-L-吡喃鼠李糖基-(1→4)]-O-β-D-吡喃葡萄糖苷(Neoprotodioscin);
化合物2:26-O-β-D-吡喃葡萄糖基-25(S)-5α-呋甾烷-2α,3β,22£,26-四羟基-3-O-[α-L-吡喃鼠李糖基-(1→2)]-O-β-D-吡喃葡萄糖苷(Trigoneoside Xa);
化合物3:25(S)-螺甾烷-2α, 3β-二羟基-3-O-[α-L-吡喃鼠李糖基-(1→2)-O-α-L-吡喃鼠李糖基-(1→4)]-O-β-D-吡喃葡萄糖苷(Tuberoside D);
化合物4:25(S)-螺甾烷-3β,5β,6α-三羟基-3- O -α-L-吡喃鼠李糖基-(1→4)-O-β-D-吡喃葡萄糖苷;
化合物5:25(S)-螺甾烷-2β, 3β, 5β -三羟基-3-O-β-D-吡喃葡萄糖苷(Tuberoside O)。化合物1至5的结构分别如下所示:
化合物1
化合物2
化合物3
化合物4
化合物5
本发明还提供了上述韭菜子提取物在制备预防和治疗肝损伤药物、食品或保健品中的应用,尤其是预防和治疗由四氯化碳引起的肝损伤。
本发明经试验发现:韭菜子提取物对四氯化碳诱导的小鼠肝损伤具有显著的保护作用,其保护机制与增强小鼠肝组织的抗氧化功能有关。因此,本发明还提供了上述韭菜子提取物在制备保护与增强肝组织抗氧化功能药物、食品或保健品中的应用。
本发明从韭菜子中提取得到含总甾体皂苷类化合物的韭菜子提取物,并采用腹腔注射四氯化碳诱导急性肝损伤小鼠模型。经实验研究发现:韭菜子提取物可以拮抗四氯化碳引起的小鼠肝组织损伤,且具有一定的保护作用,表现为减轻肝细胞炎症和纤维化,促进肝细胞再生和降低血清中天冬氨酸转氨酶、丙氨酸转氨酶的作用,可降低小鼠肝脏中MDA、NO含量;提高肝脏中T-SOD、GSH-PX酶活力,说明本发明韭菜子提取物具有加强肝损伤小鼠机体的抗氧化功能,保护肝组织免受自由基进一步伤害的作用和功效。此外,本发明韭菜子提取物制备方法简便,提取物纯度高,并且韭菜子来源广泛,取材便利,同时开拓了韭菜子提取物作为保肝护肝的保健品、食品或药物用途。
附图说明
图1为本发明韭菜子提取物对四氯化碳引起的小鼠肝损伤组织病理变化的影响。
具体实施方式
以下结合实施例对本发明的技术方案作进一步地详细介绍,但本发明的保护范围并不局限于此。
本发明中,炒韭菜子或盐炙韭菜子采用本领域常规技术制作即可,因其制作过程并非本申请的创新之所在,故此不再详述。下述实施例中,如无特殊说明,乙醇均指的是体积百分比。
实施例1
一种韭菜子提取物的制备方法,其包括如下步骤:
将5kg干燥的盐炙韭菜子粉碎后,分别用50L体积浓度50%乙醇闪式提取3次(第一次闪式提取3 min,第二次闪式提取5 min,第三次闪式提取4 min),闪式提取结束后过滤,合并三次提取获得的提取液,减压浓缩得到提取物。将提取物分散在水中,采用同体积二氯甲烷萃取3次,萃取所得水层经HPD100大孔吸附树脂吸附,然后用水冲洗至流出液无色(弃掉,主要用以除去杂质);再依次用6倍柱体积的30%乙醇、6倍柱体积60%乙醇进行梯度洗脱,合并梯度洗脱收集的洗脱液,经减压浓缩(以回收溶剂)、干燥得100.4 g提取物,即为韭菜子提取物。
本发明采用分光光度法测得上述实施例1制备所得韭菜子提取物中总甾体皂苷类化合物含量为80.1%。采用HPLC分析制备得到五种甾体皂苷类化合物,分别是化合物1:Neoprotodioscin;化合物2:Trigoneoside Xa;化合物3:Tuberoside D;化合物4:25(S)-螺甾烷-3β,5β,6α-三羟基-3- O -α-L-吡喃鼠李糖基-(1→4)-O-β-D-吡喃葡萄糖苷;化合物5:Tuberoside O。本发明对化合物1至5的理化性质和化学结构进行了定性鉴定,经MS、13C-NMR、1H-NMR测试,并与文献数据对比后确定。具体的测试结果列举如下。
化合物1:无定型白色结晶,ESI-MS: m/z 1050.0[M-H]-,根据13C-NMR和1H-NMR的核磁数据,确定分子式为:C51H86O22。1H-NMR(C5D5N) δppm谱显示有六个甲基质子信号δ0.84(3H,s,H-18),δ1.01(3H,s,H-19),δ1.00(3H,d,J=6.0Hz,H-27),δ1.26(3H,d,J=6.8Hz,H-21),δ1.73(3H,d,J=6.2Hz,H-Rha-6),δ1.60(3H,d,J=6.2Hz,H-Rha’-6);3位葡萄糖的端基氢信号δ4.91(1H,d,J=6.7Hz,H-Glc-1),26位葡萄糖的端基氢信号δ4.78(1H,d,J=8.1Hz,H-Glc’-1),与葡萄糖2位相连的鼠李糖的端基氢信号δ6.32(1H,s,H-Rha-1),以及与葡萄糖4位相连的鼠李糖的端基氢信号δ5.81(1H,s,H-Rha’-1)。13C-NMR(C5D5N) δppm显示:低场区有四个糖的端基碳信号δ99.6(C-Glc-1),δ104.8(C-Glc’-1),δ101.9(C-Rha-1),δ102.6(C-Rha’-1);δ110.4(C-22)是甾体皂苷22位的特征碳信号。与参考文献对照,该化合物为26-O-β-D-吡喃葡萄糖基-25(R)-5α-呋甾烷-3β, 22α, 26-三羟基-3-O-[α-L-吡喃鼠李糖基-(1→2)-O-α-L-吡喃鼠李糖基-(1→4)]-O-β-D-吡喃葡萄糖苷(Neoprotodioscin)。核磁数据见表1。
化合物2:无定型白色结晶,ESI-MS: m/z 1050.2[M-H]-,根据13C-NMR和1H-NMR的核磁数据,确定分子式为:C45H76O19。1H-NMR(C5D5N+H2O) δppm谱有五个甲基信号δ0.86(3H,s,H-18),δ0.89(3H,s,H-19),δ1.10(3H,d,J=6.4Hz,H-27),δ1.38(3H,d,J=6.7Hz,H-21),δ1.77(3H,d,J=6.2Hz,H-Rha-6);3位葡萄糖的端基氢信号δ5.02(1H,J=7.4Hz,H-Glc-1),鼠李糖的端基氢信号δ6.22(1H,s,H-Rha-1)以及26位葡萄糖的端基氢信号δ4.85(1H,d,J=7.8Hz,H-Glc-1)。13C-NMR(C5D5N) δppm显示:低场区有三个糖的端基碳信号δ100.4(C-Glc-1),δ104.6(C-Glc’-1),δ102.2(C-Rha-1)。δ110.6(C-22)是甾体皂苷22位的特征信号峰,δ70.4(C-2),δ84.0(C-3)是2位有羟基取代时的特征信号峰。与参考文献相比对,发现该化合物与文献中trigoneoside Xa和trigoneoside Xb碳谱核磁数据一致, 26位质子信号为δ4.06(2H,m,H-26),因此该化合物25位构型为S构型,故为26-O-β-D-吡喃葡萄糖基-25(S)-5α-呋甾烷-2α,3β,22£,26-四羟基-3-O-[α-L-吡喃鼠李糖基-(1→2)]-O-β-D-吡喃葡萄糖苷(Trigoneoside Xa)。碳谱数据见表1。
化合物3:无定型白色粉末,ESI-MS: m/z 908.9 [M+Na]+,根据13C-NMR和1H-NMR核磁数据,确定分子式为:C39H64O13。1H-NMR(CD3OD)δppm:六个甲基质子信号δ0.69(3H,s,H-18),0.79(3H,s,H-19),0.89 (3H,d,J=6.9Hz,H-21),0.99 (3H,d,J =7.0Hz,H-27),δ1.17(3H,d,J=6.4Hz,H-Rha’-6),δ1.15(3H,d,J=6.4Hz,H-Rha-6) ;三个糖的端基氢信号δ4.72(1H,d,J=7.2Hz),δ5.09(1H,s),δ5.39(1H,s);母核2位羟基质子信号δ4.40(1H,d,J=7.7Hz)。根据13C-NMR(CD3OD)δppm:低场区有三个糖的端基碳信号δ100.54(C-Glc-1),δ103.21(C-Rha-1),δ102.72(C-Rha’-1);δ111.2(C-22)是螺甾皂苷的特征碳信号,δ70.9(C-2),δ84.3(C-3)是当2位有羟基取代的特征信号,与文献对照,该化合物为25(S)-螺甾烷-2α, 3β-二羟基-3-O-[α-L-吡喃鼠李糖基-(1→2)-O-α-L-吡喃鼠李糖基-(1→4)]-O-β-D-吡喃葡萄糖苷,即Tuberoside D。碳谱数据见表1。
化合物4:无定型白色粉末,ESI-MS:m/z 779.7[M+Na]+,根据13C-NMR和1H-NMR的核磁数据,确定分子式为:C39H64O14。1H-NMR(C5D5N)谱中可以看出有葡萄糖的端基氢信号δ5.19(1H,d,J=7.2Hz,H-Glc-1),还有一个鼠李糖的端基氢信号δ5.45(1H,s,H-Rha-1),五个甲基质子信号δ0.78(3H,s,H-18),0.85(3H,s,H-19),1.08(3H,d,J=6.9Hz,H-21),0.99(3H,d,J=6.9Hz,H-27),δ1.65(3H,d,J=7.8Hz,H-Rha-6)。13C-NMR(C5D5N)δppm显示:低场区有两个糖的端基碳信号δ100.6(C-Glc-1),δ103.6(C-Rha-1);δ110.5(C-22)是螺甾烷的特征碳信号。经与文献对照,推测该化合物为25(S)-螺甾烷-3β,5β,6α-三羟基-3- O -α-L-吡喃鼠李糖基-(1→4)-O-β-D-吡喃葡萄糖苷。碳谱数据见表2。
化合物5:无定型白色粉末,ESI-MS: m/z 611.0[M+H]+,根据13C-NMR和1H-NMR数据,推测分子式:C33H54O10。1H-NMR(C5D5N)谱中可以看出有一个葡萄糖的端基氢信号δ5.04(1H,d,J=7.2Hz,H-Glc-1),四个甲基氢信号δ1.13(3H,s,H-19),0.80(3H,s,H-18),1.05(3H,d,J=7.0Hz,H-27),1.12(3H,d,J=6.8Hz,H-21)。以及部分的氢谱信号δ3.35(H-26,d,J=10.7Hz),1.79(1H,m,H-17),4.04(1H,m,H-16),3.99(1H,m,H-2),1.69(1H,m,H-25),3.87(1H,m,H-3)。13C-NMR(C5D5N)δppm:低场区有一个葡萄糖的端基碳信号δ102.3(C-Glc-1);δ109.9(C-22)是螺甾烷的特征碳信号,经与文献对照,推测化合物为25(S)-螺甾烷-2β, 3β,5β -三羟基-3-O-β-D-吡喃葡萄糖苷 (Tuberoside O)。碳谱数据见表2。
表1 化合物1—3的碳谱数据
表2 化合物4和化合物5的碳谱数据
实施例2
一种韭菜子提取物的制备方法,其包括如下步骤:
将500g干燥的韭菜子粉碎后,分别用4000mL体积浓度40%乙醇闪式提取3次(第一次闪式提取4 min,第二次闪式提取6 min,第一次闪式提取6min),闪式提取结束后过滤,合并三次提取获得的提取液,减压浓缩,得到提取物。将提取物分散在水中,采用同体积二氯甲烷萃取2次,萃取所得水层经HPD600大孔吸附树脂吸附,然后用水冲洗至流出液无色(弃掉);再依次用6倍柱体积35%乙醇、6倍柱体积55%乙醇进行梯度洗脱,合并梯度洗脱收集的洗脱液,经减压浓缩回收溶剂、干燥得10.1 g提取物,即为韭菜子提取物。采用分光光度法测得韭菜子提取物中总甾体皂苷类化合物含量为83%。
实施例3
一种韭菜子提取物的制备方法,其包括如下步骤:
将100 g干燥的炒韭菜子粉碎后,分别用1200 mL 体积浓度30%乙醇闪式提取2次(第一次提取6 min,第二次提取7min),闪式提取结束后过滤,合并两次滤液,减压浓缩,得到提取物。将提取物分散在水中,采用同体积二氯甲烷萃取3次,萃取所得水层经D101大孔吸附树脂吸附,然后用水冲洗至流出液无色(弃掉);再依次用6倍柱体积30%乙醇、6倍柱体积50%乙醇梯度洗脱,合并梯度洗脱收集的洗脱液,经减压浓缩回收溶剂、干燥得1.9g提取物,即为韭菜子提取物。采用分光光度法测得韭菜子提取物中总甾体皂苷类化合物含量为85%。
效果实验一:韭菜子提取物对四氯化碳诱导的小鼠急性肝损伤影响。
实验原料:实施例1制得的韭菜子提取物作为实验原料。
实验动物:昆明种小鼠,体重 23±2 g,SPF级,由河南省实验动物中心提供,生产批号:SCXK(豫)2017-0001。
实验试剂:见下表3。
实验仪器:见下表4。
表3. 实验试剂。
表4. 实验仪器
实验方法:将40只雄性昆明小鼠随机分成5组,每组8只,5组分别为:护肝片阳性组(60mg/kg)、韭菜子提取物低剂量组(5mg/kg)、韭菜子提取物高剂量组(15mg/kg)、空白组(给药组等体积的娃哈哈水)、四氯化碳模型组(给药组等体积的娃哈哈水)。各组分别按上述剂量灌胃给药,连续灌胃3天。第三天灌胃结束2h后,进行腹腔注射,注射体积以10ml/kg计算。模型组、阳性组、给药组腹腔注射含0.5% CCl4的橄榄油,空白组腹腔注射与模型组等体积的橄榄油,腹腔注射后小鼠禁食不禁水,24h后摘取小鼠眼球取血,将全血室温放置30-60min后进行离心(8000×g,10 min,4℃)分离收集血清,血清在使用之前应放于-80℃冰箱中保存,然后测定血清中AST(天冬氨酸转氨酶)、ALT(丙氨酸转氨酶)水平,按照试剂盒说明书的方法进行测定。采用Graphpad Prism 6统计学软件进行处理分析,结果以“± s”表示,组间比较采用One-way ANOVA 单因素方差分析,P<0.05为差异具有统计学意义。
取血后将小鼠断颈处死,剖取肝脏,用生理盐水冲洗,最后将肝脏组织放在4%的多聚甲醛溶液中保存20-24h,在无菌实验环境下用刀片将组织修剪成厚约5mm的组织,将组织依次放入脱水盒内,然后进行脱水、包埋、切片、烤片、HE染色,显微镜镜检,图像采集分析。结果见表5和图1。
与空白组比较:# P < 0.01;
与模型组比较:*P<0.05,**P<0.01。
表5的结果表明:与空白组相比,模型组的AST和ALT活力明显提高(# P<0.01),韭菜子提取物高、低剂量组的AST和ALT活力显著降低(*P<0.05,**P<0.01)。以上结果说明:本发明韭菜子提取物高、低剂量组均具有显著拮抗四氯化碳引起的小鼠肝损伤。
图1为本发明韭菜子提取物对四氯化碳引起的小鼠肝损伤组织病理变化的影响。图1的结果表明:空白组肝小叶结构完整,肝细胞结构清楚,未出现肝细胞坏死、细胞核变性及炎症细胞浸润等病理特征,细胞质均匀,中央静脉清晰可见,细胞形态整体正常;四氯化碳模型组肝脏细胞结构遭到损坏,可以明显看到细胞核出现破裂变性现象,且有炎症细胞浸润中央静脉,肝小叶结构不完整;护肝片阳性组和本发明韭菜子提取物高、低剂量组总体上肝细胞正常,细胞核结构正常,中央静脉清晰可见,无或较少炎症细胞浸润,细胞质均匀。
效果实验二:总甾体皂苷的抗氧化试验
实验动物:成年昆明小鼠,雄性,体重23± 2g,80只,分为5组,每组16只。即护肝片阳性组(60mg/kg)、韭菜子提取物低剂量组(5mg/kg)、韭菜子提取物高剂量组(15mg/kg)空白组(给药组等体积的娃哈哈水)、四氯化碳模型组(给药组等体积的娃哈哈水)。各组分别按上述剂量灌胃给药,连续灌胃3天。第三天灌胃结束2h后,注射体积以10ml/kg计算。模型组、阳性组、给药组腹腔注射含0.5% CCl4的橄榄油,空白组腹腔注射与模型组等体积的橄榄油。腹腔注射后小鼠禁食不禁水,24h后剖取肝脏。
主要试剂盒:一氧化氮(NO)、超氧化物歧化酶(T-SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-PX)以上试剂均为南京建成生物工程研究所生产。
主要仪器:UV-2000 型紫外可见分光光度计 (尤尼可上海仪器有限公司) ;Multiskan Go1510 酶标仪 (Thermo Scientific);LRH-150 恒温培养箱 (上海一恒科技有限公司);TGL- 16G台式离心机(上海安亭科学仪器厂)。
实验方法:实验操作按照试剂盒说明书进行,测定小鼠肝组织NO、MDA的含量,以及T-SOD、GSH-PX酶活力,结果见表6。
与空白组比较:#P < 0.01;
与模型组比较:**P<0.01。
表6的结果显示:给药组与模型组比较,本发明韭菜子提取物高、低剂量组均能显著降低CCl4急性给药后小鼠肝中的NO、MDA含量,并且均能显著提高肝中T-SOD酶和GSH-PX酶活性。结果表明:本发明韭菜子提取物对小鼠肝组织氧化性损伤有保护作用,通过增强小鼠肝组织的抗氧化功能,避免肝组织被自由基的进一步伤害。
Claims (5)
1.韭菜子提取物在制备预防和治疗肝损伤药物、或者在制备保护与增强肝组织抗氧化功能药物中的应用,其特征在于,将粉碎后的韭菜子、炒韭菜子或盐炙韭菜子用20-50%乙醇进行闪式提取,提取液浓缩后分散在水中,然后用二氯甲烷进行萃取,萃取所得水层部位经大孔吸附树脂吸附后用水冲洗,最后用30-60%乙醇进行梯度洗脱,合并梯度洗脱所得的洗脱液,经浓缩、干燥即得。
2. 如权利要求1 所述韭菜子提取物在制备预防和治疗肝损伤药物、或者在制备保护与增强肝组织抗氧化功能药物中的应用,其特征在于,闪式提取2-3次,闪式提取时每1 g韭菜子、炒韭菜子或盐炙韭菜子添加8-15mL的20-50%乙醇。
3. 如权利要求1 所述韭菜子提取物在制备预防和治疗肝损伤药物、或者在制备保护与增强肝组织抗氧化功能药物中的应用,其特征在于,每次闪式提取的时间为3-10min。
4.如权利要求1所述韭菜子提取物在制备预防和治疗肝损伤药物、或者在制备保护与增强肝组织抗氧化功能药物中的应用,其特征在于,二氯甲烷萃取次数为2-3次。
5.如权利要求1所述韭菜子提取物在制备预防和治疗肝损伤药物、或者在制备保护与增强肝组织抗氧化功能药物中的应用,其特征在于,所述大孔吸附树脂的型号为HPD100,HPD600,HPD400,D101,AB-8,ADS-17或DM130。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811353323.3A CN109276637B (zh) | 2018-11-14 | 2018-11-14 | 韭菜子提取物及其制备方法和在制备保肝护肝药物方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811353323.3A CN109276637B (zh) | 2018-11-14 | 2018-11-14 | 韭菜子提取物及其制备方法和在制备保肝护肝药物方面的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109276637A CN109276637A (zh) | 2019-01-29 |
CN109276637B true CN109276637B (zh) | 2021-07-20 |
Family
ID=65176222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811353323.3A Active CN109276637B (zh) | 2018-11-14 | 2018-11-14 | 韭菜子提取物及其制备方法和在制备保肝护肝药物方面的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109276637B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115487263B (zh) * | 2022-10-19 | 2023-08-18 | 劲牌有限公司 | 一种抑制6-磷酸葡萄糖脱氢酶的韭菜子提取物的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101040997A (zh) * | 2007-04-19 | 2007-09-26 | 哈尔滨医科大学 | 韭菜籽总皂苷的提取方法及其应用 |
-
2018
- 2018-11-14 CN CN201811353323.3A patent/CN109276637B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101040997A (zh) * | 2007-04-19 | 2007-09-26 | 哈尔滨医科大学 | 韭菜籽总皂苷的提取方法及其应用 |
Non-Patent Citations (2)
Title |
---|
闪式提取技术在中药成分提取中的研究进展;黄越燕等;《中国医院药学杂志》;20150131;第35卷(第1期);第83-87页,尤其是第83-84页第1.2节第1段,第2.3节第1段 * |
韭菜子总皂苷水解产物对Hela细胞毒性评价;李国玉等;《2009医学前沿论坛暨第十一届全国肿瘤药理与化疗学术会议论文集》;20090409;第134页,尤其是最后一段 * |
Also Published As
Publication number | Publication date |
---|---|
CN109276637A (zh) | 2019-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nguyen et al. | Triterpenoids from the genus Gynostemma: Chemistry and pharmacological activities | |
Rameshrad et al. | Saffron and its derivatives, crocin, crocetin and safranal: a patent review | |
US7811997B2 (en) | Composition containing total triterpenoid sapogenins extracted from bamboo, and the preparation method and use thereof | |
TWI454269B (zh) | 由文冠果(xanthoceras sorbifolia)單離之化合物、其製備方法以及其用途 | |
AU2004200624B2 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same | |
CN108610387B (zh) | 一种具有神经细胞保护活性的四个异黄烷苷类化合物及其制备方法 | |
CN109200045A (zh) | 花色苷提取物在制备防治蒽环类药物心肌细胞毒性的药物组合物中的应用及药物组合物 | |
CN102114102B (zh) | 一种具有保肝利胆作用的中药提取物混合制剂及其应用 | |
KR20140108621A (ko) | 돌외의 지페노사이드 추출물을 포함하는 제2형 당뇨병, 비만 또는 고지혈증의 치료 또는 예방용 조성물 | |
Mishra et al. | Jiao gu lan (gynostemma pentaphyllum): The chinese rasayan-current research scenario | |
CN109276637B (zh) | 韭菜子提取物及其制备方法和在制备保肝护肝药物方面的应用 | |
CN113999272A (zh) | 香蜂草苷的制备方法及其应用 | |
CN108976264A (zh) | 一种补肾、益精血、防辐射雪莲淫羊藿红景天中药组合物 | |
CN109867649B (zh) | 一种双黄酮类化合物及其制备方法与应用 | |
CN109091602B (zh) | 韭菜子有效成分、提取方法及其在制备保护肝损伤药物方面的应用 | |
CN113876754B (zh) | 黑果枸杞花青素提取物及冻干粉的制备方法和在防治糖尿病性白内障产品中的应用 | |
CN102558128B (zh) | 含银杏原花青素提取物的制备方法 | |
CN105998104B (zh) | 一种榆钱提取物在制备治疗神经保护药物方面的用途 | |
TWI389701B (zh) | 沉香屬果殼之萃取物及其於治療癌症之用途 | |
CN101822705A (zh) | 桔梗总皂苷及单体桔梗皂苷d在解酒药物中的应用 | |
CN111329866B (zh) | 一种五环三萜类化合物在制备抗偏头痛药物中的应用 | |
CN109223739B (zh) | 一种组合物及其制备方法和应用 | |
CN108969555B (zh) | 一种补肾、益精血、增强免疫力的淫羊藿中药组合物的制备方法 | |
CN109771468A (zh) | 杜仲雄花有效部位及其制备方法和应用 | |
CN115073376B (zh) | 附子中的c20二萜生物碱、其制备及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |